Assessment of venetoclax in combination with Ibrutinib in patients with Chronic Lymphocytic Leukaemia

Submission date	Recruitment status No longer recruiting Overall study status	[X] Prospectively registered		
09/03/2016		☐ Protocol		
Registration date		Statistical analysis plan		
09/03/2016	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
05/01/2024	Cancer			

Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-venetoclax-and-ibrutinib-for-chronic-lymphocytic-leukaemia-clarity

Contact information

Type(s)

Public

Contact name

Ms Rebecca Bishop

Contact details

University of Birmingham Institute for Cancer studies Edgbaston Birmingham United Kingdom B15 2TT

Additional identifiers

Clinical Trials Information System (CTIS)

2015-003422-14

Protocol serial number

20572

Study information

Scientific Title

CLARITY: Assessment of VenetoCLAx (ABT-199) in combination with IbRutInib in relapsed /refracTory Chronic LymphocYtic Leukaemia

Acronym

CLARITY

Study objectives

The aim of this study is to increase the effectiveness of ibrutinib by using it in combination with Venetoclax to assess if this is the ideal combination of drug to use and hope that patients can be treated with lower toxicity than standard treatments.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Yorkshire & The Humber – Leeds East Research Ethics Committee, 21/12/2015, ref: 15/YH/0530

Study design

Multi-centre non-randomised study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cancer; Subtopic: Cancer (Haematological Oncology); Disease: Leukaemia (Chronic Lymphocytic Leukaemia)

Interventions

Ibrutinib: Continuous Ibrutinib treatment of 420mg once daily Venetoclax: Venetoclax treatment for a maximum of 24 months

Intervention Type

Other

Primary outcome(s)

Proportion of patients with <0.01% MRD in the blood and bone marrow at 12 months.

Key secondary outcome(s))

- 1. Biological response is monitored throughout the duration of the trial
- 2. Overall Survival is determined from the date of registration to date of death
- 3. Progression-free survival (PFS) is monitored throughout the duration of the trial
- 4. Proportion of patients with <0.01% MRD in the blood and bone marrow is measured after 6 and 24 months of combination therapy
- 5. Response rate is determined using the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) criteria after 12 and 24 months of combination therapy
- 6. Toxicity of combination therapy is measured throughout the duration of trial

29/10/2022

Eligibility

Key inclusion criteria

- 1. Aged 18 and over
- 2. Able to give informed consent
- 3. Diagnosis of CLL, requiring therapy according to IWCLL criteria (appendix 1)
- 4. CLL should be assessable for MRD by flow cytometry (CD19, CD5 and CD23 and CD43 co-expression with weak CD20, CD79b/slg & CD81 expression; to be confirmed by HMDS)
- 5. Refractory/relapsed CLL defined as any of the following:
- 5.1. Failure to achieve a response (CR or PR by IWCLL Criteria) to a purine analogue alone or in combination with chemotherapy
- 5.2. Relapse within 6 months of responding to a purine analogue alone or in combination with chemotherapy
- 5.3. Relapse at any time after the combination of fludarabine, cyclophosphamide and rituximab (FCR) or bendamustine plus rituximab (or other equivalent monoclonal anti-CD20 antibodies)
- 5.4. Patients with CLL with deletion of chromosome 17p who have progressed after at least one previous therapy
- 6. ECOG performance status (PS) of 0, 1, or 2
- 7. Prepared to undergo the stipulated investigations within the trial (including bone marrow examinations)
- 8. Adequate bone marrow function (defined below) independent of growth factor or transfusion support, within 2 weeks of screening unless cytopenia is clearly due to marrow involvement of CLL:
- 8.1. Platelet count $\geq 75 \times 109/L$; in cases of thrombocytopenia clearly due to marrow involvement of CLL (per the discretion of the investigator), platelet count should be $\geq 30 \times 109/L$ independent of transfusion
- 8.2. Absolute neutrophil count (ANC) \geq 1.0 x 109/L unless neutropenia is clearly due to marrow involvement of CLL (per the discretion of the investigator)
- 8.3. Total haemoglobin \geq 90 g/L unless anaemia is due to marrow involvement of CLL (per the discretion of the investigator)
- 9. Adequate renal and hepatic function at screening:
- 9.1. Calculated creatinine clearance \geq 50 mL/min using 24-hour creatinine clearance or modified Cockcroft-Gault equation (using ideal body mass [IBM] instead of mass): eCCR=((140-Age)>IBM (kg).[0.85 if female])/(72.Serum creatinine (mg/dL)) Or, if serum creatinine is in μ mol/L: eCCR= ((140-Age)>IBM (kg).[1.23 if male,1.04 if female])/(Serum creatinine (μ mol/L)) IBM (kg) = ([height in cm-154] \times 0.9)] + (50 if male, 45.5 if female)
- 10. AST or ALT≤ 3.0 times the upper limit of normal (ULN) of the institution's normal range 11. Bilirubin ≤ 1.5 × ULN. Patients with known Gilbert's syndrome may have a bilirubin level > 1.5 × ULN
- 12. Prothrombin time (or international normalised ratio) and partial thromboplastin time not to exceed 1.2 times the institution's normal range

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

53

Key exclusion criteria

- 1. Transformation of CLL to aggressive NHL (e.g. Richter's transformation, prolymphocytic leukaemia, or diffuse large B-cell lymphoma or CNS involvement by CLL)
- 2. A history of any severe, concurrent renal, neurological, psychiatric, endocrine, metabolic, immunologic, cardiac, pulmonary or hepatic diseases that could interfere with the patient's ability to participate in the study
- 3. Use of prior investigational agents within 28 days of planned treatment
- 4. Females who are pregnant or lactating
- 5. Females of childbearing potential (or males whose partners are of childbearing potential) who are unwilling to use appropriate contraception during and for 3 months following treatment
- 6. Mantle cell lymphoma
- 7. Known to be HIV positive
- 8. Positive test results for chronic hepatitis B infection (defined as positive HBsAg serology)
- 9. Positive test results for hepatitis C (HCV antibody serology testing). Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
- 10. Active secondary malignancy excluding basal cell carcinoma
- 11. Patients requiring or who have received anticoagulation treatment with warfarin or vitamin K antagonists within 1 week of registration
- 12. Patients requiring concomitant use of strong CYP3A4/5 inhibitors/inducers within 7 days prior to registration
- 13. Previous treatment with Ibrutinib, venetoclax or an alternative Btk or Bcl-2 inhibitor
- 14. Inability to tolerate uric acid reducing medications Undergone an allogeneic stem cell transplant unless beyond 6 months post-transplant and off immune suppressive therapy with no evidence of Graft-versus-Host disease
- 15. Known hypersensitivity to either of the compounds or to its excipients
- 16. Patients who have received an anti-CLL monoclonal antibody within 8 weeks prior to registration
- 17. A cardiovascular disability status of New York Heart Association Class ≥ 3 (Class 3 is defined as cardiac disease in which patients are comfortable at rest but have marked limitation of physical activity due to fatigue, palpitations, dyspnoea or angina pain)
- 18. Major surgery within 30 days prior to registration
- 19. Vaccination with a live vaccine within 28 days prior to registration
- 20. Steroid therapy for anti-neoplastic intent will not be allowed either during or within 7 days prior to registration with the exception of inhalational steroids for the treatment of asthma or COPD, topical steroids, replacement corticosteroid therapy for an inherited or acquired deficiency

Date of first enrolment

01/04/2016

Date of final enrolment 01/12/2017

Locations

Countries of recruitment

United Kingdom

England

Northern Ireland

Scotland

Wales

Study participating centre Belfast City Hospital

Lisburn Road Belfast United Kingdom BT9 7AB

Study participating centre University Hospital of Wales

Heath Park Cardiff United Kingdom CF14 4XW

Study participating centre Christie Hospital

550 Wilmslow Road Manchester United Kingdom M20 4BX

Study participating centre Churchill Hospital

Old Road Headington Oxford United Kingdom OX3 7LE

Study participating centre Beatson West of Scotland Cancer Centre

1053 Great Western Road Glasgow United Kingdom G12 0YN

Study participating centre Hammersmith Hospital

Du Cane Road London United Kingdom W12 0HS

Study participating centre King's College Hospital

Denmark Hill London United Kingdom SE5 9RS

Study participating centre Nottingham City Hospital

Hucknall Road Nottingham United Kingdom NG5 1PB

Study participating centre Queen Elizabeth Hospital

Queen Elizabeth Medical Centre Birmingham United Kingdom B15 2TH

Study participating centre Royal Liverpool University Hospital

Prescot Street Liverpool United Kingdom L7 8XP

Study participating centre Southampton General Hospital

Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre St Bartholomew's Hospital

W Smithfield London United Kingdom EC1A 7BE

Study participating centre St James' Hospital

Beckett Street Leeds United Kingdom LS9 7TF

Sponsor information

Organisation

University of Birmingham

ROR

https://ror.org/03angcq70

Funder(s)

Funder type

Government

Funder Name

Leukaemia and Lymphoma Research

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	20/10/2019	11/06/2020	Yes	No
Basic results	version 1.0	03/01/2024	05/01/2024	No	No
HRA research summary	Participant information sheet		28/06/2023	No	No
Participant information sheet		11/11/2025	11/11/2025	No	Yes
Plain English results			23/02/2021	No	Yes